# Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

> **NCT06167694** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 146 (estimated)

## Conditions studied

- Unresectable or Metastatic Breast Cancer

## Interventions

- **DRUG:** HRS-8080; Dalpiciclib Isethionate Tablets

## Key facts

- **NCT ID:** NCT06167694
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167694, "Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06167694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*